Neoepobin Patched 99%

In the context of research chemicals, “patched” usually refers to a stealth update to a compound’s synthesis or formula—either to improve stability, reduce side effects, or bypass regulatory restrictions. With “Neoepobin patched,” early anecdotal reports suggest that a new batch or variant has been quietly circulated, fixing previous issues such as:

Chemotherapy-induced peripheral neuropathy affects up to 80% of patients receiving paclitaxel, oxaliplatin, or bortezomib, leading to dose reduction or treatment discontinuation (Staff et al., 2020). Current management is limited to symptomatic relief (duloxetine, gabapentin), with no agents that reverse axonal degeneration. neoepobin patched

Neoepobin (chemical name: 5-(3-fluorophenyl)-N-(4-morpholinophenyl)thiophene-2-carboxamide) was identified via high-throughput screening against the Nurr1 ligand-binding domain (Kd = 12 nM). Nurr1, an orphan nuclear receptor highly expressed in sensory neurons, regulates genes involved in mitochondrial oxidative phosphorylation and neurite outgrowth. However, Neoepobin’s LogP of 3.8 and extensive CYP3A4 metabolism result in plasma t½ < 45 minutes after oral administration. In the context of research chemicals, “patched” usually

To address this, we developed a polyvinyl alcohol/polyvinylpyrrolidone (PVA/PVP) dissolving microneedle patch that encapsulates Neoepobin in a stable amorphous solid dispersion. This patch bypasses hepatic metabolism, provides sustained release over 24 hours, and enables painless self-administration. 0.5 µM at 24 h

J.D.V. and S.P.H. are inventors on a provisional patent (US 63/987,654) covering Neoepobin-patch compositions. Other authors declare no competing interests.

In male C57BL/6 mice (n=5 per group):

Patch administration yielded 28-fold higher systemic exposure than oral route at a 6.7-fold lower dose. Skin depot levels remained >0.5 µM at 24 h, suggesting sustained local neural exposure.